Drug or treatment

Glofitamab clinical trials

• 36Clinical trials
• 21Countries

Newest trials

All recruiting trials (36)

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

• Glofitamab with R-CHOP for Newly Diagnosed HIV-Related Large B-Cell Lymphoma

  This phase 1 study tests glofitamab plus R-CHOP chemoimmunotherapy in adults newly diagnosed with HIV-related large B-cell lymphoma to see if the regimen is safe and tolerable.

  Recruiting Phase 1 National Cancer Institute (NCI) · Rockville, Maryland · NCT07649304

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

• Glofitamab plus lenalidomide for high‑risk relapsed or refractory mantle cell lymphoma after a BTK inhibitor

  This trial tests whether giving glofitamab with oral lenalidomide helps adults with high‑risk mantle cell lymphoma that has returned or not responded after prior treatments including a BTK inhibitor.

  Recruiting Phase 2 Peking University Third Hospital · Beijing, Beijing Municipality · NCT07460362

• Glofitamab for mantle cell lymphoma after CAR-T failure

  This phase 2, multicenter, single-arm study tests glofitamab in adults with mantle cell lymphoma who did not respond to or relapsed after CAR-T cell therapy.

  Recruiting Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria and 13 other locations · NCT07453095

• Glofitamab as a Bridge to and/or Consolidation After Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma

  This trial tests glofitamab in adults with relapsed or refractory DLBCL to see if using it around autologous stem cell transplant helps or improves outcomes.

  Recruiting Phase 2 American University of Beirut Medical Center · Beirut · NCT07387848

• BTKi‑rituximab induction followed by glofitamab consolidation for high‑risk newly diagnosed mantle cell lymphoma

  This will test whether giving glofitamab after initial BTKi plus rituximab helps control high‑risk, newly diagnosed mantle cell lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07257055

• Glofitamab plus PD‑1 antibody and lenalidomide for relapsed/refractory TP53‑aberrant large B‑cell lymphoma

  This trial will test whether combining glofitamab with a PD‑1 antibody and lenalidomide can help adults with relapsed or refractory large B‑cell lymphoma that has TP53 mutations or deletions.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07240194

• Glofitamab for Chinese adults with second-line relapsed or refractory diffuse large B‑cell lymphoma

  This will test whether glofitamab-based therapy helps and is safe for Chinese adults whose diffuse large B‑cell lymphoma returned or didn't respond after one prior treatment.

  Recruiting at 22 sites Hoffmann-La Roche · Langfang, Hebei and 21 other locations · NCT07200375

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• Real-world outcomes with glofitamab for large B-cell lymphoma

  This project looks at how well glofitamab works and how safe it is for adults in France with relapsed or refractory large B‑cell lymphoma who were treated through the expanded access program.

  Recruiting at 30 sites The Lymphoma Academic Research Organisation · Argenteuil and 29 other locations · NCT06994169

• Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma

  This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06922604

• Hypofractionation Radiotherapy + Glofitamab in Relapsed/Refractory DLBCL with High Tumor Burden

  This study tests whether giving hypofractionated radiotherapy together with glofitamab helps people with relapsed/refractory DLBCL and large tumors see better responses.

  Recruiting Phase 2 Huazhong University of Science and Technology · Wuhan, Hubei · NCT06867536

• Evaluating Glofitamab with Gemcitabine and Oxaliplatin for Lymphoma

  This study is testing a new combination treatment of glofitamab, gemcitabine, and oxaliplatin for people with relapsed or hard-to-treat lymphoma to see how well it works and if it causes side effects.

  Recruiting at 45 sites Phase 2 Hoffmann-La Roche · Anchorage, Alaska and 52 other locations · NCT06806033

• Treatment for Diffuse Large B-cell Lymphoma using Glofitamab

  This study is testing a new combination of treatments for people with diffuse large B-cell lymphoma to see if it works better and has fewer side effects than current options.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT06765317

• Glofitamab treatment for patients with relapsed or refractory DLBCL before stem cell transplant

  This study is testing if Glofitamab can help patients with relapsed or hard-to-treat diffuse large B-cell lymphoma get ready for a stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06682130

• Combining radiation therapy with lenalidomide and glofitamab for treating relapsed DLBCL

  This study is testing a new treatment combining radiation therapy with lenalidomide and glofitamab to see if it helps people with relapsed diffuse large B-cell lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06651853

• Combining Glofitamab and Chidamide for treating recurrent DLBCL

  This study is testing if a combination of two medications, Glofitamab and Chidamide, can help adults with recurring diffuse large B-cell lymphoma feel better.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06570447

• Evaluating Glofitamab with Venetoclax and Zanubrutinib for high-risk Mantle-cell Lymphoma

  This study is testing a new combination of treatments for people with high-risk Mantle-cell Lymphoma to see if it helps them better than current options.

  Recruiting at 16 sites Phase 2 The Lymphoma Academic Research Organisation · Bruges and 15 other locations · NCT06558604

• Treatment for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

  This study is testing a new treatment called MEN1703, alone and with another drug, to see if it helps people with aggressive B-cell non-Hodgkin lymphoma who haven't responded to other treatments.

  Recruiting at 29 sites Phase 2 Ryvu Therapeutics SA · Le Mans and 34 other locations · NCT06534437

• Evaluating glofitamab for patients with relapsed or refractory DLBCL in China

  This study is testing if glofitamab can safely help Chinese patients with relapsed or refractory diffuse large B-cell lymphoma who haven't responded to previous treatments.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06481826

• Glofitamab plus ibrutinib and obinutuzumab for mantle cell lymphoma

  This trial will see if combining glofitamab with ibrutinib and obinutuzumab is safe and effective for adults with previously untreated, high‑risk or age‑65‑and‑older mantle cell lymphoma.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06357676

• Combining glofitamab and pirtobrutinib for treating relapsed or refractory mantle cell lymphoma

  This study is testing if combining two drugs, glofitamab and pirtobrutinib, can help people with relapsed or refractory mantle cell lymphoma feel better and live longer.

  Recruiting at 4 sites Phase 2 University of California, San Francisco · Davis, California and 3 other locations · NCT06252675

• Combining axicabtagene ciloleucel and glofitamab for treating relapsed large B cell lymphoma

  This study is testing if combining two treatments, axicabtagene ciloleucel and glofitamab, can help people with relapsed large B cell lymphoma feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06213311

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Evaluating Glofitamab for Relapsed Mantle Cell Lymphoma

  This study is testing if a new treatment called glofitamab can work better than standard options for people with relapsed mantle cell lymphoma.

  Recruiting at 62 sites Phase 3 Hoffmann-La Roche · Berkeley, California and 82 other locations · NCT06084936

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

• Combination therapy for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with mantle cell lymphoma that hasn't responded to previous treatments.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06054776

• Using Glofitamab to Improve Treatment for Untreated Diffuse Large B Cell Lymphoma

  This study is testing if adding a new drug called glofitamab to standard treatment can help people with untreated diffuse large B cell lymphoma have better outcomes.

  Recruiting at 2 sites Phase 2 University Health Network, Toronto · Toronto, Ontario and 2 other locations · NCT06050694

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Combination treatment for newly diagnosed high-risk mantle cell lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed high-risk mantle cell lymphoma to see if it helps them live longer without the disease getting worse.

  Recruiting at 3 sites Phase 1/2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT05861050

• Combining Glofitamab and Pirtobrutinib for Mantle Cell Lymphoma

  This study is testing if combining two drugs, Glofitamab and Pirtobrutinib, can help people with relapsed or hard-to-treat Mantle Cell Lymphoma feel better and possibly achieve complete remission.

  Recruiting at 2 sites Phase 2 Australasian Leukaemia and Lymphoma Group · Parkville, Victoria and 1 other locations · NCT05833763

• Glofitamab and Polatuzumab with R-CHP for high-risk diffuse large B-cell lymphoma

  This will test whether adding the immunotherapies glofitamab and polatuzumab to standard R-CHP chemotherapy helps adults with previously untreated high-risk diffuse large B-cell lymphoma.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT05800366

• Evaluating Glofitamab for Pediatric and Young Adult Patients with Relapsed B-Cell Non-Hodgkin Lymphoma

  This study is testing a new treatment called glofitamab, alone and with standard chemotherapy, to see if it helps kids and young adults with relapsed B-cell non-Hodgkin lymphoma feel better.

  Recruiting at 30 sites Phase 1/2 Hoffmann-La Roche · Birmingham, Alabama and 29 other locations · NCT05533775

Quick answers

How many clinical trials of Glofitamab are recruiting right now?

36, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (16 trials), China (13 trials), France (7 trials), Australia (4 trials), Italy (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 27, Phase 1/2: 3, Phase 1: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →